ArticleScience translational medicine2016

A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.

Robert A Scott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.